News

DEA Witness Denial Sparks Outcry Among Psychedelic Advocates

DEA Witness Denial Sparks Outcry Among Psychedelic Advocates

DEA Witness Denial Sparks Outcry Among Advocates

The Drug Enforcement Administration (DEA) has caused quite a stir by denying testimony from important witnesses just before scheduled hearings on the potential classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). This decision has led to significant backlash from advocates, most notably the Students for Sensible Drug Policy (SSDP), who claim the DEA is stifling essential scientific discussions.

DEA Blocks Testimonies And Exhibits

In a recent motion, the DEA aimed to exclude witnesses and exhibits suggested by SSDP, Panacea Plant Sciences, and Dr. Raul A. Ramos. The agency deemed the evidence supplied as “incompetent, irrelevant, immaterial, and/or unduly repetitious.” Moreover, the motion criticized the format of the exhibits, stating they lacked proper pagination and identification marks, complicating their submission ahead of the hearings spanning November 12-22, with a conclusive session on November 25.

The DEA questioned the expertise of some witnesses proposed by SSDP, particularly focusing on David Heldreth, CEO of Panacea. The agency argued that Heldreth was “not offered as an expert” and lacked the scientific credentials necessary to provide testimony regarding the pharmacological effects of DOI or DOC, deeming his testimony about potential risks as merely speculative.

SSDP Fights Back

This rejection has ignited fierce opposition from SSDP and its legal representatives. Robert Rush, a Denver attorney working with SSDP, expressed his concern by questioning what the DEA is afraid of in blocking voices of preeminent scientists. He criticized the agency for attempting to silence these respected experts in neuroscience and pharmacology.

Elijah Ullman, chair of SSDP’s Science Policy Committee, also voiced his frustrations, pointing out that their proposed witnesses have extensive knowledge in the relevant fields. “We have gathered a world-class international group of experts including behavioral and molecular pharmacologists, chemists, neuroscientists, and even a former Government Advisor on psychoactive drugs,” Ullman stated. He is currently pursuing his Ph.D. in molecular and systems pharmacology at Emory University.

Ullman believes the DEA’s refusal to acknowledge expert testimonies reflects a lack of confidence in their own data, suggesting that had the agency truly believed in the validity of their claims, they would allow the proposed witnesses to testify. It appears there are serious doubts regarding the scientific rigor behind the DEA’s assertions.

Following the rejection of witnesses, SSDP filed an additional motion in the DEA Administrative Court, pushing back against the denial.

The Fight Over DOI And DOC

The DEA has been pushing to classify DOI and DOC as Schedule I substances since April 2022, a classification that signifies harmful drugs with no recognized medical benefits and a high abuse potential. This classification is contentious, with SSDP and Panacea Plant Sciences taking a strong stand against it by legally contesting the DEA's decisions. They argue that these compounds offer promising avenues for scientific exploration and therapeutic applications.

Although an initial lawsuit challenging the DEA's actions was dismissed, SSDP and its partners have remained steadfast in their efforts to fight the proposed classification through upcoming hearings.

What's At Stake?

The implications of the DEA’s proposed ban are far-reaching. If enacted, it would greatly restrict researchers' abilities to study DOI and DOC, both of which hold potential therapeutic value for psychedelic-assisted therapies. Advocates fear that labeling these substances as Schedule I would severely impede scientific research and curtail opportunities to investigate their potential benefits.

Frequently Asked Questions

What compound classifications are being discussed by the DEA?

The DEA is considering classifying 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I substances.

Why did the DEA deny witness testimonies?

The DEA deemed that the proposed testimonies were incompetent or irrelevant and lacked proper formatting, which raised concerns about their inclusion in hearings.

How has the SSDP responded to the DEA's actions?

SSDP has actively criticized the DEA, arguing that the rejection of expert testimonies reflects an attempt to suppress essential scientific discussions.

What are the potential uses of DOI and DOC?

DOI and DOC are believed to have therapeutic uses in psychedelic-assisted therapies and research into their effects could yield significant advancements.

What does the Schedule I classification entail?

Schedule I classification indicates a substance has no accepted medical use and a high potential for abuse, which can heavily restrict research opportunities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 148

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 112

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Thread AI Joins Microsoft Pegasus: Big AI Leap

Updated Category News Views 26

Thread AI Leaps Ahead with Microsoft Partnership There's excitement in the air as Thread AI joins forces with Microsoft by entering the exclusive Pegasus Program. In the ever-evolving world of AI, making a splash this big doesn't happen every day. People in the tech alley are buzzing, and it looks like Thread AI is ready to rumble on a larger stage—much like a scrappy...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 86

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading

Top 5 Most Recently Viewed Articles

Evogene Partners with Academic Leader to Combat Metabolic Disorders

Updated Category News Views 174

Evogene's Innovative Collaboration Evogene Ltd. (NASDAQ: EVGN) has entered into an exciting partnership with Professor Ehud Gazit from Tel Aviv University to develop innovative therapeutics aimed at metabolic diseases. Understanding Metabolic Diseases Metabolic diseases often arise from the inability of the body to break down specific metabolites. This inability can lead...

Continue Reading
Farasis Energy's Rise in Solid-State Battery Rankings Explained

Updated Category News Views 505

Farasis Energy's Notable Achievement in Battery Technology Recently, Farasis Energy gained recognition as a leading contender in the 2024 China Solid-State Battery Competitiveness Rankings, marking a significant milestone in the company's journey. As a global frontrunner in electric vehicle (EV) battery solutions, Farasis Energy has established robust partnerships with...

Continue Reading
Building a Reliable Future with Weilliptic's Advanced AI

Updated Category News Views 310

Weilliptic: Pioneering Autonomous and Trustworthy AI In the rapidly evolving landscape of technology, Avinash Lakshman, a serial entrepreneur renowned for creating Amazon Dynamo and Apache Cassandra, is leading the charge towards a new foundational infrastructure that merges AI and blockchain into a cohesive and verifiable framework. This innovative platform, known as...

Continue Reading
Navigating Investor Rights: Aehr Test Systems Case Insights

Updated Category News Views 169

Aehr Test Systems Investor Rights and Securities Fraud Lawsuit Investors in Aehr Test Systems (NASDAQ: AEHR) find themselves at a critical juncture. The Rosen Law Firm, renowned for its advocacy on behalf of investors, has issued important reminders regarding a securities fraud lawsuit that centers on Aehr Test Systems. Understanding the Class Period The timeline for this...

Continue Reading
Understanding Andersons' Earnings and Market Performance Insights

Updated Category News Views 276

Anticipating Earnings from Andersons Inc Andersons Inc (NASDAQ: ANDE) is gearing up to share its quarterly earnings report soon. This announcement is of considerable interest to both existing shareholders and potential investors. It's vital to stay informed about what to expect before the company reveals its financial results. Projected Earnings and Market Sentiments...

Continue Reading